Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EPS (Basic): 2023-2024

Historic EPS (Basic) for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to -$2.18.

  • Contineum Therapeutics' EPS (Basic) fell 7.55% to -$0.57 in Q4 2024 from the same period last year, while for Dec 2024 it was -$4.91, marking a year-over-year decrease of 76.62%. This contributed to the annual value of -$2.18 for FY2024, which is 260.29% down from last year.
  • Per Contineum Therapeutics' latest filing, its EPS (Basic) stood at -$2.18 for FY2024, which was down 260.29% from $1.36 recorded in FY2023.
  • In the past 5 years, Contineum Therapeutics' EPS (Basic) registered a high of $1.36 during FY2023, and its lowest value of -$2.18 during FY2024.
  • In the last 2 years, Contineum Therapeutics' EPS (Basic) had a median value of -$0.41 in 2023 and averaged -$0.41.
  • Data for Contineum Therapeutics' EPS (Basic) shows a maximum YoY plummeted of 260.29% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Contineum Therapeutics' EPS (Basic) stood at $1.36 in 2023, then tumbled by 260.29% to -$2.18 in 2024.